openPR Logo
Press release

OTC Cough, Cold & Allergy Medicine Market Highlighting Lucrative Avenues Across Major Geographies during 2017-2022

01-22-2019 11:45 AM CET | Health & Medicine

Press release from: Fact.MR

Fact.MR’s recently published report reveals that the  OTC cough, cold and allergy medicine market is set to witness 4.9% between 2017 and 2022. This market is estimated to stand at around US$ 37,323 Mn towards the end of the forecast period.

A large number of people across the globe purchase OTC (over-the-counter) medicines for treating minor cough, cold or allergy related problems rather visiting the doctor. This has been a major reason behind the incessant sales of OTC cough, cold and allergy drugs

Key Players:

Key companies profiled in Fact.MR’s report include Sanofi-Aventis, Johnson & Johnson Service, Inc., Reckitt Benckiser Group Plc., Novartis AG, GlaxoSmithKline Plc., AstraZaneca Plc., Pfizer Inc., Sun Pharmaceutical Industries Ltd.,

Request Sample Report

https://www.factmr.com/connectus/sample?flag=S&rep_id=71

The OTC cough, cold and allergy medicine market is segmented as follows:

Drug Type
OTC Channel
Dosage

Browse Full Report on OTC cough, cold and allergy medicine market with TOC-

https://www.factmr.com/report/71/otc-cough-cold-allergy-medicine-market

Global-OTC cough, cold and allergy medicine market report has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the market space. The report also includes Porter's five force model, SWOT analysis, company profiling, business strategies of market players and their business models.The market study conducted on the basis of primary as well as secondary research where the analysts fragment the data from various databases such as Bloomberg, Factiva, Owler and others. Our primary research team conducted various interviews, surveys and group discussions of industry professionals.

The report’s succeeding section focuses on drivers, restraints and key trends from macroeconomic, demand, and supply perspectives. Impact analysis of weighted average model-based growth drivers is contained in the report for better provision of decision-making insights to clients.

On the basis of drug type, antihistamine is anticipated to command for over one-third revenues share of the market by the end of2017.  Antihistamines drugs help in restricting the histamine release from histamine-1 receptors, moreover these drugs can effectively treat watery eyes or runny nose, inflammation (redness), sneezing and swelling (edema).

To Buy OTC cough, cold and allergy medicine market Report-

https://www.factmr.com/checkout/71/S

OTC cough, cold and allergy medicine market – Regional Overview & Competitive Backdrop A comprehensive section on the regional analysis of global OTC cough, cold and allergy medicine market is included in the report. North America, Europe, Japan, Asia-Pacific excluding Japan (APEJ), Latin America, and Middle East & Africa are key regions into which the expansion of global OTC cough, cold and allergy medicine market is studied.

Geographically, Asia-Pacific excluding Japan (APEJ) to Remain the Largest Market for OTC Cough, Cold and Allergy Medicines

 The OTC cough, cold and allergy medicines market in Asia Pacific excluding Japan (APEJ) is anticipated to remain highly attractive throughout the assessment period. In 2017 and beyond, the region is projected to command for a noteworthy revenue share of the global market.

For More Information Send Enquiry:

https://www.factmr.com/connectus/sample?flag=AE&rep_id=71

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Email: sales@factmr.com

Web: https://www.factmr.com/

Read Industry News at - https://www.industrynewsanalysis.com/

 

 

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release OTC Cough, Cold & Allergy Medicine Market Highlighting Lucrative Avenues Across Major Geographies during 2017-2022 here

News-ID: 1520867 • Views:

More Releases from Fact.MR

Triple Negative Breast Cancer Treatment Market is Growing at a CAGR of 4.6% by 2034 | Key players: Pfizer Inc., F. Hoffman-La Roche Ltd., Sanofi S.A., and Seattle Genetics, and Genentech.
10-03-2025 | Health & Medicine
Fact.MR
Triple Negative Breast Cancer Treatment Market is Growing at a CAGR of 4.6% by 2 …
Fact.MR today unveiled its latest report on the Triple Negative Breast Cancer Treatment Market, projecting steady yet impactful growth amid rising global breast cancer incidences and a push for innovative therapies targeting this aggressive subtype. Valued at USD 670.5 million in 2024, the global market is forecasted to expand at a compound annual growth rate (CAGR) of 4.6%, reaching USD 1.04 billion by 2034. This expansion underscores the urgent need
Pulmonary Fibrosis Treatment Market: U.S. to Grow to US$ 4.06 Billion by 2034, Led by Roche, Boehringer Ingelheim & Others
10-03-2025 | Health & Medicine
Fact.MR
Pulmonary Fibrosis Treatment Market: U.S. to Grow to US$ 4.06 Billion by 2034, L …
The global pulmonary fibrosis treatment market is poised for steady expansion, with its valuation projected to grow from USD 3,210 million in 2025 to USD 5,890 million by 2035. This growth reflects a compound annual growth rate (CAGR) of 6.2% over the forecast period from 2025 to 2035. The surge is primarily driven by the increasing prevalence of idiopathic pulmonary fibrosis (IPF), rising awareness of early diagnosis, and advancements in
Spices and Seasonings Market is Projected to Reach USD 23.6 Billion by 2035 | McCormick & Company, Associated British Foods, Olam International, Sensient Technologies, Kerry Group
10-03-2025 | Food & Beverage
Fact.MR
Spices and Seasonings Market is Projected to Reach USD 23.6 Billion by 2035 | Mc …
The global spices and seasonings market is set for significant growth, projected to expand from USD 14.5 billion in 2025 to USD 23.6 billion by 2035, achieving an absolute increase of USD 8.3 billion and a 57.2% overall growth. This trajectory reflects a compound annual growth rate (CAGR) of 5.0% over the forecast period from 2025 to 2035, representing a 1.57X market size increase. The expansion is driven by rising
Accounting Services Market: U.S. to Grow to US$ 640.73 Billion by 2034 at 10.3% CAGR, Supported by PwC, EY, Deloitte & KPMG
Accounting Services Market: U.S. to Grow to US$ 640.73 Billion by 2034 at 10.3% …
The global accounting services market is positioned for substantial growth, with its valuation projected to increase from USD 650 billion in 2025 to USD 1,250 billion by 2035. This expansion reflects a compound annual growth rate (CAGR) of 6.7% over the forecast period from 2025 to 2035. The market's surge is driven by the increasing complexity of financial regulations, the digital transformation of businesses, and the rising demand for outsourced

All 5 Releases


More Releases for OTC

Lawsuit filed for Investors who lost money with shares of adidas AG (OTC: ADDYY, …
An investor, who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), filed a lawsuit over alleged violations of Federal Securities Laws by adidas AG in connection with certain allegedly false and misleading statements. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 27, 2023. adidas AG (OTC: ADDYY, OTC: ADDDF) investors should contact
Investigation for Investors in adidas AG (OTC: ADDYY, OTC: ADDDF) announced over …
An investigation on behalf of investors in shares of adidas AG (OTC: ADDYY, OTC: ADDDF) was announced over potential breaches of fiduciary duties by certain officers and directors at adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain adidas AG officers and
AMERICAN HEMP VENTURES INC (OTC: AMHV) TO BECOME YOUNEEQAI TECHNICAL SERVICES In …
FOR IMMEDIATE RELEASE Denver Colorado, March 31, 2023, American Hemp Ventures, Inc. (OTC: AMHV) announced today that its name has changed effective immediately to YouneeqAI Technical Services inc. (OTC: YQAI) reflecting the Company's new focus into cookie-less AI technology services. The current management team has over 50 years of experience in technology services and innovation. Murray Galbraith, YQAI's CEO, is the Founder of YouneeqAI's software solution and has operated several private technology
Investigation announced for Investors who lost money with shares of adidas AG (O …
An investigation was announced for investors of adidas AG (OTC: ADDYY, OTC: ADDDF) shares over potential securities laws violations by adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of adidas AG (OTC: ADDYY,
Fuel Cell Market Technological Trends and Business Opportunities 2021 To 2026; P …
MarketInsightsReports has published a report titled global Fuel Cell Market research report 2021 that is a detailed observation of several aspects, including the rate of growth, technological advances, and different methodologies implemented by the primary current market players. The report is based on a collective analysis of data, which is obtained through primary and secondary research. It provides a systematic approach to the current and prospective scenario of this market. The
Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF). Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to